{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:19:28Z","timestamp":1784665168088,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006701","name":"Umm Al-Qura University","doi-asserted-by":"publisher","award":["26UQU4310387GSSR01"],"award-info":[{"award-number":["26UQU4310387GSSR01"]}],"id":[{"id":"10.13039\/501100006701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119259","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:10:26Z","timestamp":1773843026000},"page":"119259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immune checkpoint targeted drug conjugate therapies: Bridging preclinical and clinical innovation for solid tumor therapy"],"prefix":"10.1016","volume":"198","author":[{"given":"Waleed H.","family":"Almalki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119259_bib1","doi-asserted-by":"crossref","first-page":"10217","DOI":"10.1021\/jacs.3c14005","article-title":"Nanomedicine remodels tumor microenvironment for solid tumor immunotherapy","volume":"146","author":"Guo","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2026.119259_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall\u2019Olio","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119259_bib3","first-page":"20","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol. Cancer 2025 241."},{"key":"10.1016\/j.biopha.2026.119259_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis","volume":"82","author":"Rezaee-Zavareh","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119259_bib5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","article-title":"Beyond the blood: expanding CAR T cell therapy to solid tumors","volume":"43","author":"Uslu","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119259_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-025-56527-0","article-title":"Unlocking the potential of engineered immune cell therapy for solid tumors","volume":"16","author":"Albarr\u00e1n-Fern\u00e1ndez","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119259_bib7","first-page":"1","article-title":"Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment","volume":"9","author":"Marchesi","year":"2025","journal-title":"Npj Precis. Oncol."},{"key":"10.1016\/j.biopha.2026.119259_bib8","first-page":"783","article-title":"Cellular polarity pilots breast cancer progression and immunosuppression","volume":"44","author":"Huang","year":"2025","journal-title":"Oncogene 2025 4412"},{"key":"10.1016\/j.biopha.2026.119259_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.biopha.2026.119259_bib10","unstructured":"Study Details | A Study of PF-08046054\/SGN-PDL1V in Advanced Solid Tumors | ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/study\/NCT05208762?cond=NCT05208762&rank=1\u3009 (accessed August 17, 2025)."},{"key":"10.1016\/j.biopha.2026.119259_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41423-024-01245-8","article-title":"Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors","volume":"22","author":"Catanzaro","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.biopha.2026.119259_bib12","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.3390\/curroncol30040323","article-title":"Metastatic castration-resistant prostate cancer, immune checkpoint inhibitors, and beyond","volume":"30","author":"Lanka","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.biopha.2026.119259_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41419-023-06389-5","article-title":"Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks","volume":"15","author":"Meng","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2026.119259_bib14","first-page":"51","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2024","journal-title":"Br. J. Cancer 2024 1321."},{"key":"10.1016\/j.biopha.2026.119259_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110417","article-title":"Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: from theory to therapy","volume":"120","author":"Guo","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2026.119259_bib16","unstructured":"Study Details | Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/study\/NCT04145622?cond=NCT04145622&rank=1\u3009 (accessed August 17, 2025)."},{"key":"10.1016\/j.biopha.2026.119259_bib17","unstructured":"Study Details | Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/study\/NCT05280470?cond=NCT05280470&rank=1\u3009 (accessed August 19, 2025)."},{"key":"10.1016\/j.biopha.2026.119259_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall\u2019Olio","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119259_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119259_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10555-025-10260-8","article-title":"Lessons learned from a decade of immune checkpoint inhibition: the good, the bad, and the ugly","volume":"44","author":"Adashek","year":"2025","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.biopha.2026.119259_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2026.119259_bib22","unstructured":"Study Details | A Phase I\/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies | ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/study\/NCT05123482?cond=NCT05123482&rank=1\u3009 (accessed August 20, 2025)."},{"key":"10.1016\/j.biopha.2026.119259_bib23","first-page":"372","article-title":"Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma","volume":"6","author":"Jammihal","year":"2025","journal-title":"Nat. Cancer 2025 62."},{"key":"10.1016\/j.biopha.2026.119259_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383456","article-title":"Targeting PD-1\/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges","volume":"15","author":"Javed","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119259_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ccell.2025.01.004","article-title":"Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity","volume":"43","author":"Braun","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2026.119259_bib26","unstructured":"Study Details | A Study of Felmetatug Vedotin\/SGN-B7H4V in Advanced Solid Tumors | ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/study\/NCT05194072?cond=NCT05194072&rank=1\u3009 (accessed August 20, 2025)."},{"key":"10.1016\/j.biopha.2026.119259_bib27","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.biopha.2026.119259_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102614","article-title":"Novel targets for immune-checkpoint inhibition in cancer","volume":"120","author":"Borgeaud","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.biopha.2026.119259_bib29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/clinpract13010003","article-title":"The role of immune checkpoint inhibitors in cancer therapy","volume":"13","author":"Basudan","year":"2022","journal-title":"Clin. Pr."},{"key":"10.1016\/j.biopha.2026.119259_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01364-7","article-title":"Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119259_bib31","first-page":"3575","article-title":"Immune checkpoint inhibitors in cancer therapy\u2014how to overcome drug resistance?","volume":"14","author":"Lao","year":"2022","journal-title":"Cancers 2022"},{"key":"10.1016\/j.biopha.2026.119259_bib32","unstructured":"Study Details | AMG 172 First in Human Study in Patients With Kidney Cancer | ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/study\/NCT01497821?cond=NCT01497821&rank=1\u3009 (accessed August 20, 2025)."},{"key":"10.1016\/j.biopha.2026.119259_bib33","article-title":"FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119259_bib34","first-page":"320","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects","volume":"11","author":"Tang","year":"2022","journal-title":"Cells 2022"},{"key":"10.1016\/j.biopha.2026.119259_bib35","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","article-title":"Phase i dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma","volume":"32","author":"Tannir","year":"2014","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.biopha.2026.119259_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","article-title":"Immune checkpoint inhibitors for cancer and venous thromboembolic events","volume":"158","author":"Gong","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119259_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-023-06389-5","article-title":"Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks","volume":"15","author":"Meng","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2026.119259_bib38","unstructured":"Study Details | Study of MDX-1203 in Subjects With Advanced\/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed\/Refractory B-Cell Non-Hodgkin\u2019s Lymphoma (B-NHL) | ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/study\/NCT00944905?cond=NCT00944905&rank=1\u3009 (accessed August 20, 2025)."},{"key":"10.1016\/j.biopha.2026.119259_bib39","unstructured":"Study Details | Study of MDX-1203 in Subjects With Advanced\/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed\/Refractory B-Cell Non-Hodgkin\u2019s Lymphoma (B-NHL) | ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/study\/NCT00944905?cond=NCT00944905&rank=1\u3009 (accessed August 16, 2025)."},{"key":"10.1016\/j.biopha.2026.119259_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13091339","article-title":"Antibody\u2013drug conjugates for the treatment of renal cancer: a scoping review on current evidence and clinical perspectives","volume":"13","author":"Sganga","year":"2023","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.biopha.2026.119259_bib41","unstructured":"Study Details | A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/study\/NCT03530397?cond=NCT03530397&rank=1\u3009 (accessed August 16, 2025)."},{"key":"10.1016\/j.biopha.2026.119259_bib42","first-page":"232","article-title":"PDL-1 antibody drug conjugate for selective chemo-guided immune modulation of cancer","volume":"11","author":"Sau","year":"2019","journal-title":"Cancers 2019"},{"key":"10.1016\/j.biopha.2026.119259_bib43","unstructured":"Study Details | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/study\/NCT03543813?cond=NCT03543813&rank=1\u3009 (accessed August 16, 2025)."},{"key":"10.1016\/j.biopha.2026.119259_bib44","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1111\/cas.16205","article-title":"LAG-3: recent developments in combinational therapies in cancer","volume":"115","author":"Chavanton","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2026.119259_bib45","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1158\/1535-7163.MCT-16-0393","article-title":"Development of a novel antibody-drug conjugate for the potential treatment of ovarian, lung, and renal cell carcinoma expressing TIM-1","volume":"15","author":"Thomas","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119259_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70212","article-title":"Promising new anti-TIGIT agents: stealthy allies in cancer immunotherapy","volume":"18","author":"Srikanth","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.biopha.2026.119259_bib47","doi-asserted-by":"crossref","first-page":"19216","DOI":"10.1021\/acs.jmedchem.4c01652","article-title":"Advancing cancer immunotherapy through engineering new PD-L1 degraders: a comprehensive study from small molecules to PD-L1-specific peptide-drug conjugates","volume":"67","author":"Zeng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119259_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004590","article-title":"PD-L1\/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way","volume":"10","author":"Yu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2026.119259_bib49","first-page":"3575","article-title":"Immune checkpoint inhibitors in cancer therapy\u2014how to overcome drug resistance?","volume":"14","author":"Lao","year":"2022","journal-title":"Cancers 2022"},{"key":"10.1016\/j.biopha.2026.119259_bib50","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119259_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119259_bib52","first-page":"1","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119259_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119259_bib54","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.3390\/jcm12134301","article-title":"Review of the immune checkpoint inhibitors in the context of cancer treatment","volume":"12","author":"Alturki","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2026.119259_bib55","doi-asserted-by":"crossref","DOI":"10.4110\/in.2022.22.e2","article-title":"Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy","volume":"22","author":"Lee","year":"2022","journal-title":"Immune Netw."},{"key":"10.1016\/j.biopha.2026.119259_bib56","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat. Rev. Rheuma"},{"key":"10.1016\/j.biopha.2026.119259_bib57","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.3390\/jcm12134301","article-title":"Review of the immune checkpoint inhibitors in the context of cancer treatment","volume":"12","author":"Alturki","year":"2023","journal-title":"J. Clin. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:51:20Z","timestamp":1779245480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226002921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":57,"alternative-id":["S0753332226002921"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119259","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint targeted drug conjugate therapies: Bridging preclinical and clinical innovation for solid tumor therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119259"}}